Goldman Sachs’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-279,225
| Closed | -$3.13M | – | 4458 |
|
|
2017
Q3 | $3.13M | Sell |
279,225
-51,430
| -16% | -$576K | ﹤0.01% | 2635 |
|
|
2017
Q2 | $3.64M | Buy |
330,655
+103,534
| +46% | +$1.14M | ﹤0.01% | 2447 |
|
|
2017
Q1 | $2.23M | Sell |
227,121
-117,993
| -34% | -$1.16M | ﹤0.01% | 2666 |
|
|
2016
Q4 | $3.73M | Buy |
345,114
+22,372
| +7% | +$242K | ﹤0.01% | 2358 |
|
|
2016
Q3 | $3.31M | Buy |
322,742
+25,953
| +9% | +$266K | ﹤0.01% | 2452 |
|
|
2016
Q2 | $3.88M | Sell |
296,789
-103,132
| -26% | -$1.35M | ﹤0.01% | 2272 |
|
|
2016
Q1 | $4.4M | Buy |
399,921
+120,916
| +43% | +$1.33M | ﹤0.01% | 2140 |
|
|
2015
Q4 | $2.57M | Buy |
279,005
+88,647
| +47% | +$816K | ﹤0.01% | 2396 |
|
|
2015
Q3 | $1.32M | Sell |
190,358
-3,364
| -2% | -$23.3K | ﹤0.01% | 2763 |
|
|
2015
Q2 | $1.9M | Buy |
193,722
+19,371
| +11% | +$190K | ﹤0.01% | 2582 |
|
|
2015
Q1 | $1.55M | Sell |
174,351
-2,108
| -1% | -$18.7K | ﹤0.01% | 2676 |
|
|
2014
Q4 | $1.55M | Buy |
176,459
+93,831
| +114% | +$822K | ﹤0.01% | 2662 |
|
|
2014
Q3 | $569K | Buy |
82,628
+9,317
| +13% | +$64.2K | ﹤0.01% | 3247 |
|
|
2014
Q2 | $385K | Buy |
73,311
+464
| +0.6% | +$2.44K | ﹤0.01% | 3514 |
|
|
2014
Q1 | $331K | Sell |
72,847
-11,419
| -14% | -$51.9K | ﹤0.01% | 3626 |
|
|
2013
Q4 | $425K | Buy |
84,266
+10,746
| +15% | +$54.2K | ﹤0.01% | 3509 |
|
|
2013
Q3 | $372K | Sell |
73,520
-15,955
| -18% | -$80.7K | ﹤0.01% | 3497 |
|
|
2013
Q2 | $443K | Buy |
+89,475
| New | +$443K | ﹤0.01% | 3240 |
|